JP2024019727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024019727A5 JP2024019727A5 JP2023223638A JP2023223638A JP2024019727A5 JP 2024019727 A5 JP2024019727 A5 JP 2024019727A5 JP 2023223638 A JP2023223638 A JP 2023223638A JP 2023223638 A JP2023223638 A JP 2023223638A JP 2024019727 A5 JP2024019727 A5 JP 2024019727A5
- Authority
- JP
- Japan
- Prior art keywords
- sgrna
- nme
- nucleotides
- length
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584310P | 2017-11-10 | 2017-11-10 | |
| US62/584,310 | 2017-11-10 | ||
| US201762596375P | 2017-12-08 | 2017-12-08 | |
| US62/596,375 | 2017-12-08 | ||
| US201862667084P | 2018-05-04 | 2018-05-04 | |
| US62/667,084 | 2018-05-04 | ||
| JP2020525971A JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
| PCT/US2018/060126 WO2019094791A2 (en) | 2017-11-10 | 2018-11-09 | Targeted crispr delivery platforms |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525971A Division JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024019727A JP2024019727A (ja) | 2024-02-09 |
| JP2024019727A5 true JP2024019727A5 (enExample) | 2025-04-17 |
Family
ID=66438139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525971A Withdrawn JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
| JP2023223638A Pending JP2024019727A (ja) | 2017-11-10 | 2023-12-28 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525971A Withdrawn JP2021502097A (ja) | 2017-11-10 | 2018-11-09 | 標的化ｃｒｉｓｐｒ送達プラットフォーム |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20220389447A9 (enExample) |
| EP (1) | EP3707254A4 (enExample) |
| JP (2) | JP2021502097A (enExample) |
| KR (2) | KR102922730B1 (enExample) |
| CN (1) | CN111868240A (enExample) |
| AU (2) | AU2018364993B2 (enExample) |
| BR (1) | BR112020009268A2 (enExample) |
| CA (1) | CA3082370A1 (enExample) |
| CO (1) | CO2020007046A2 (enExample) |
| IL (2) | IL317505A (enExample) |
| MX (1) | MX2020004777A (enExample) |
| SG (1) | SG11202005103RA (enExample) |
| WO (1) | WO2019094791A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7250031B2 (ja) * | 2018-09-25 | 2023-03-31 | 公益財団法人微生物化学研究会 | 新規ウイルスベクターおよびその製造方法と使用方法 |
| EP3921638A4 (en) | 2019-02-05 | 2022-08-24 | AMMR Joint Venture | EXPANDED CHOICE OF EFFICIENT TARGETED GENE MANIPULATORS |
| US20220298494A1 (en) * | 2019-02-14 | 2022-09-22 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| CN110257406B (zh) * | 2019-06-21 | 2022-07-22 | 安徽省农业科学院水稻研究所 | 密码子植物化改造的Plant Nme2Cas9基因及其应用 |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| WO2021122944A1 (en) | 2019-12-18 | 2021-06-24 | Alia Therapeutics Srl | Compositions and methods for treating retinitis pigmentosa |
| CN113652411B (zh) * | 2021-07-30 | 2025-01-10 | 复旦大学 | Cas9蛋白、含有Cas9蛋白的基因编辑系统及应用 |
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| WO2023064813A2 (en) * | 2021-10-13 | 2023-04-20 | University Of Massachusetts | Modified guide rnas for neisseria meningitidis cas9 |
| CA3237303A1 (en) | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
| IL312507A (en) * | 2021-11-03 | 2024-07-01 | Intellia Therapeutics Inc | Modified guide rnas for gene editing |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| KR20250124819A (ko) | 2022-12-21 | 2025-08-20 | 인텔리아 테라퓨틱스, 인크. | 프로단백질 전환효소 서브틸리신 켁신 9(pcsk9) 편집을 위한 조성물 및 방법 |
| TW202436622A (zh) | 2023-03-06 | 2024-09-16 | 美商英特利亞醫療公司 | 用於ｂ型肝炎病毒（ｈｂｖ）基因體編輯之組合物及方法 |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013266968B2 (en) * | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| RU2716420C2 (ru) * | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
| EP3666892A1 (en) * | 2013-07-10 | 2020-06-17 | President and Fellows of Harvard College | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
| CA2930877A1 (en) * | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| JP2016538001A (ja) * | 2013-11-28 | 2016-12-08 | ホライズン・ジェノミクス・ゲーエムベーハー | 体細胞半数体ヒト細胞株 |
| JP6793547B2 (ja) * | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| EP3080259B1 (en) * | 2013-12-12 | 2023-02-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| WO2016049258A2 (en) * | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
| US10190106B2 (en) * | 2014-12-22 | 2019-01-29 | Univesity Of Massachusetts | Cas9-DNA targeting unit chimeras |
| WO2016179038A1 (en) * | 2015-05-01 | 2016-11-10 | Spark Therapeutics, Inc. | ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE |
| US11732258B2 (en) * | 2016-11-02 | 2023-08-22 | President And Fellows Of Harvard College | Engineered guide RNA sequences for in situ detection and sequencing |
| BR112019028146A2 (pt) * | 2017-07-31 | 2020-07-07 | Sigma-Aldrich Co. Llc | rna guia sintético para sistemas ativadores de crispr/cas |
-
2018
- 2018-11-09 IL IL317505A patent/IL317505A/en unknown
- 2018-11-09 IL IL274526A patent/IL274526B2/en unknown
- 2018-11-09 EP EP18876344.5A patent/EP3707254A4/en active Pending
- 2018-11-09 KR KR1020207016690A patent/KR102922730B1/ko active Active
- 2018-11-09 MX MX2020004777A patent/MX2020004777A/es unknown
- 2018-11-09 SG SG11202005103RA patent/SG11202005103RA/en unknown
- 2018-11-09 KR KR1020267003248A patent/KR20260023096A/ko active Pending
- 2018-11-09 US US16/186,352 patent/US20220389447A9/en not_active Abandoned
- 2018-11-09 AU AU2018364993A patent/AU2018364993B2/en active Active
- 2018-11-09 CA CA3082370A patent/CA3082370A1/en active Pending
- 2018-11-09 BR BR112020009268-1A patent/BR112020009268A2/pt unknown
- 2018-11-09 WO PCT/US2018/060126 patent/WO2019094791A2/en not_active Ceased
- 2018-11-09 CN CN201880082218.2A patent/CN111868240A/zh active Pending
- 2018-11-09 JP JP2020525971A patent/JP2021502097A/ja not_active Withdrawn
-
2020
- 2020-06-10 CO CONC2020/0007046A patent/CO2020007046A2/es unknown
-
2023
- 2023-01-06 AU AU2023200084A patent/AU2023200084B2/en active Active
- 2023-12-28 JP JP2023223638A patent/JP2024019727A/ja active Pending
-
2024
- 2024-03-21 US US18/612,111 patent/US20250223611A1/en active Pending
- 2024-12-13 US US18/980,456 patent/US20250197889A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024019727A5 (enExample) | ||
| Parambi et al. | Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases | |
| AU2019258678B2 (en) | Lipid-based formulations for the delivery of RNA | |
| Rettig et al. | Progress toward in vivo use of siRNAs-II | |
| Trapani et al. | Has retinal gene therapy come of age? From bench to bedside and back to bench | |
| Sago et al. | Cell subtypes within the liver microenvironment differentially interact with lipid nanoparticles | |
| BR112017012482B1 (pt) | Composição, usos de uma composição, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção da composição | |
| CN115869332A (zh) | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 | |
| WO2023124740A1 (zh) | 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用 | |
| CN120019152A (zh) | 用于表达蛋白质的人工多核苷酸 | |
| Leclerc et al. | Next-generation biological vector platforms for in vivo delivery of genome editing agents | |
| JP2024511808A (ja) | ウイルスベクターに基づくｒｎａ送達システム及びその使用 | |
| JP2022523806A (ja) | 閉端ｄｎａ（ｃｅｄｎａ）および免疫調節化合物 | |
| Mathew et al. | Heat-shrinking DNA nanoparticles for in vivo gene delivery | |
| KR20220007601A (ko) | 치료제 투여를 위한 조성물 및 방법 | |
| KR102685034B1 (ko) | 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체 | |
| WO2024236361A1 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| CN119998457A (zh) | 基于金属纳米颗粒-核酸缀合物的基因载体 | |
| EP3836903B1 (en) | Lipid-based formulations containing salts for the delivery of rna | |
| Chand et al. | Advances in Gene Therapy for Neurologic Disorders: An Overview | |
| Singh et al. | The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions | |
| CN118634243B (zh) | Mir2911在制备抗登革病毒denv的药物中的应用 | |
| US20250376664A1 (en) | Virus-Ribonucleoprotein Conjugates | |
| RU2815001C2 (ru) | Составы на основе липидов для доставки рнк | |
| NZ805346A (en) | Targeted crispr delivery platforms |